This study reports two year results from a randomized clinical trial examining myopia control spectacle lenses with highly aspherical lenslets (HAL) or slightly aspherical lenslets (SAL). The findings showed the HAL lens controlled refractive and axial progression by 50-55% and SAL by around 30% over two years. Read more about the outcomes and comparisons to other myopia control spectacles here.
This systematic review of 9 studies confirms that under-correction of myopia does not slow progression; rather, at least half of the studies have shown the myopia progression is accelerated. There was no benefit found in overcorrection, and the evidence for un-correction was equivocal. Clinically, this advocates for the full correction of myopia.
When looking through the ‘treatment zones’ of three different types of myopia controlling spectacle lenses with lenslets, visual acuity is reduced by 3-5 letters and mid-to-high frequency contrast sensitivity is mildly affected compared to single vision spectacles. We’re yet to learn if small differences between designs may influence patient preference.
This study reports two year results from a randomized clinical trial examining Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for myopia control. The findings showed around 50% refractive and 60% axial length efficacy in Hong Kong Chinese children, with an absolute effect of 0.44D lower refraction and 0.34mm less axial elongation in DIMS wearers.
This study reports one year results from an ongoing randomized clinical trial examining spectacle lenses with highly aspherical lenslet (HAL) or slightly aspherical lenslet (SAL) technology. The findings showed the HAL lens controlled refractive and axial progression by 60-70% and SAL by 30-40% over the first 12 months.